Analyzer-free quantitative diagnostics platform delivering lab-grade tests anywhere in minutes.
Vidcare has developed Mu-Sure, a patented microfluidic platform enabling instrument-free, quantitative blood tests. By removing instruments and analyzers entirely, we make high-quality diagnostic testing simple, scalable, and deployable anywhere, starting with TSH and HbA1c for chronic disease management at point of care.
Equity: ~4.7 Cr with Lavni Ventures and Social Alpha as largest investors. Grants and cash awards from BIRAC, IIGP 2.0, P&G, NIDHI, HDFC Bank, etc.
Vidcare holds 6 granted global patents across the US, Europe, China, Japan, Brazil, and India, covering broad innovations in microfluidic diagnostics, analyte quantification, and instrument-free point-of-care testing. They also have 2 active filings and 2 additional patents under drafting.
Winner, India Innovation Growth Program 2.0 (2019); Winner, P&G Health Vision Award at Slingshot Singapore (2021); Silver, IFIA Innovacities Competition, Brazil.
A 7-member core deep-tech team with backgrounds from IITs, TU Delft, TU Dresden, Wageningen University, University of Glasgow, and TISS, offering expertise in microfluidics, biochemistry, assay development, clinical operations, and med-tech business, led by founders with over 25 years of collective domain experience, multiple granted global patents, and significant product development and go-to-market success.
Founder
Co-founder
